What are the common and serious side effects of medications used to treat attention-deficit/hyperactivity disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ADHD Medication Side Effects

ADHD medications are generally safe with mostly mild-to-moderate side effects, but require monitoring for specific cardiovascular, growth, and psychiatric parameters—with stimulants causing primarily appetite loss, sleep disturbances, and headaches, while nonstimulants carry distinct risks including sedation (guanfacine/clonidine) and rare suicidality (atomoxetine). 1

Stimulant Medications (Methylphenidate, Amphetamines)

Common Side Effects

The most frequent adverse effects are:

  • Decreased appetite (most common)
  • Abdominal pain
  • Headaches
  • Sleep disturbances/insomnia 1, 2

Growth Effects

Monitor height and weight regularly. Stimulants decrease growth velocity by 1-2 cm from predicted adult height, particularly with higher, consistently administered doses. This effect diminishes by the third year but shows no compensatory rebound growth. 1

Cardiovascular Effects

Stimulants cause mild, clinically insignificant increases on average:

  • Heart rate: 1-2 beats per minute
  • Blood pressure: 1-4 mm Hg (systolic and diastolic) 1

However, 5-15% of patients experience more substantial HR and BP increases, requiring vital sign monitoring. 1

Critical point: Despite concerns, stimulants do NOT increase sudden cardiac death risk beyond baseline rates in children not receiving stimulants. 1 The risk of serious cardiovascular events is extremely low. 3

Pre-Treatment Cardiac Screening Required

Before initiating stimulants, obtain:

  • Personal history of cardiac symptoms
  • Family history of:
    • Sudden death
    • Wolff-Parkinson-White syndrome
    • Hypertrophic cardiomyopathy
    • Long QT syndrome 1

If any risk factors present, obtain ECG and consider cardiology referral before starting medication. 1

Psychiatric Side Effects

  • Hallucinations and psychotic symptoms (uncommon but significant) 1
  • Some evidence suggests elevated risk of psychosis and tics, though case reports show remission upon discontinuation 4

Nonstimulant Medications

Atomoxetine

Monitor for suicidality—FDA black box warning present. 1, 2

Common adverse effects:

  • Decreased appetite
  • Initial somnolence
  • Gastrointestinal symptoms (especially with rapid dose escalation)
  • Headache
  • Stomach pain 1, 2

Rare but serious: Hepatitis (extremely rare) 1

Growth effects: Similar to stimulants—delays in first 1-2 years with return to expected measurements after 2-3 years, primarily in children taller/heavier than average pre-treatment. 1

Cardiovascular: Increases HR and BP similar to stimulants. Obtain cardiac history and ECG if risk factors present. 1

Key advantage: Fewer appetite/growth problems compared to stimulants. 2

Guanfacine and Clonidine (Extended-Release)

Monitor pulse and blood pressure—these medications DECREASE both parameters. 1, 2

Common adverse effects:

  • Somnolence/sedation (frequent—administer in evening preferably)
  • Fatigue
  • Dry mouth
  • Dizziness
  • Irritability
  • Headache
  • Bradycardia
  • Hypotension
  • Abdominal pain 1, 2

Critical warning: NEVER abruptly discontinue—taper to avoid rebound hypertension. 1

Monitoring Parameters by Medication Class

All ADHD Medications

  • Height (growth velocity)
  • Weight
  • Pulse
  • Blood pressure 2

Atomoxetine Specifically

  • Suicidality assessment
  • Clinical worsening 2

Common Pitfalls to Avoid

  1. Failing to obtain cardiac history before initiation—this is non-negotiable for both stimulants and nonstimulants 1

  2. Abruptly stopping guanfacine/clonidine—always taper to prevent rebound hypertension 1

  3. Not monitoring growth parameters—both stimulants and atomoxetine affect growth trajectories 1

  4. Ignoring the 5-15% who have substantial cardiovascular changes—regular vital sign monitoring catches these patients 1

  5. Rapid atomoxetine dose escalation—increases GI side effects; titrate slowly 1

Onset of Side Effects vs. Benefits

Stimulants: Rapid onset of both benefits AND side effects 2

Nonstimulants:

  • Atomoxetine: 6-12 weeks for full effect
  • Guanfacine/Clonidine: 2-4 weeks for full effect 2

This delayed benefit profile means side effects may appear before therapeutic effects with nonstimulants, requiring patient/family counseling about expectations.

Serious but Rare Events

The risk of serious cardiovascular adverse events, QTc prolongation, and sudden cardiac death is extremely low across all ADHD medications at therapeutic doses. 3 No reports of torsades de pointes clearly related to ADHD medications exist. 3

The benefits of treating ADHD outweigh cardiovascular risks after adequate assessment, but exercise great caution with personal/family history of cardiovascular disease. 3

References

Related Questions

What are the first-line pharmacologic treatment options and dosing recommendations for attention-deficit/hyperactivity disorder in children, adolescents, and adults?
What is the relationship between Attention Deficit Hyperactivity Disorder (ADHD) and sensitivity to narcotics and other medications with sedative properties?
What is the recommended acute and chronic management for a 27‑year‑old woman with attention‑deficit/hyperactivity disorder, inappropriate sinus tachycardia syndrome and recurrent supraventricular tachycardia (heart rates 180–200 bpm) that worsens with positional changes, with stable blood pressure and otherwise normal laboratory studies?
In a 9-year-old child with attention-deficit/hyperactivity disorder (ADHD) who weighs 77 lb (≈35 kg) and is 60 in tall, what medication should be started?
In a child with vague abdominal pain, a normal physical examination, and a history of attention-deficit/hyperactivity disorder (ADHD), what are the appropriate next steps in evaluation and management?
What intramuscular dose of ceftriaxone (Rocephin) should be given to a patient weighing 32.26 kg?
What is the appropriate treatment for filarial lymphadenitis?
What nutrients should be monitored and supplemented in adults with non‑traumatic brain injury (e.g., ischemic stroke, intracerebral hemorrhage, hypoxic‑ischemic encephalopathy)?
What is the appropriate management of persistent hypertension 7 weeks postpartum in a patient who had preeclampsia?
What dexamethasone intramuscular dose should be administered to a patient weighing 32.26 kg?
What pupillary abnormalities may be observed in a patient with acute alcohol intoxication and six days of total blindness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.